Stock listing
NASDAQ:TRAX First Tracks Biotherapeutics, Inc. Stock
Home listing (NASDAQ) of First Tracks Biotherapeutics, Inc.
Follow First Tracks Biotherapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TRAX
$41.64 USD -2.86 (-6.4%)
Close on Nov 20, 2026
- Day range
- $41.51 – $44.51 USDNov 20, 2026
- Volume
- 504,364 sharesNov 20, 2026
- Market cap
- $1.75B USDAt the close on Nov 20, 2026 · price × 42.02M shares outstanding
- Traded on an average day
- $32.33M USDMedian day 617,731 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TRAX · Home | $41.64 USD | -2.86 (-6.4%) | 504,364 | $43.99 | $44.51 | $41.51 | $44.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TRAX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $41.64 | -2.86 | -6.4% | $43.99 | $44.51 | $41.51 | 504,364 | |
| $44.50 | +0.93 | +2.1% | $43.17 | $45.44 | $43.17 | 751,346 | |
| $43.57 | -2.99 | -6.4% | $46.04 | $46.71 | $43.06 | 586,451 | |
| $46.56 | -0.54 | -1.1% | $46.52 | $48.48 | $46.29 | 438,162 | |
| $47.10 | -1.60 | -3.3% | $48.54 | $48.72 | $46.58 | 462,165 | |
| $48.70 | -1.83 | -3.6% | $48.94 | $50.15 | $46.97 | 311,332 | |
| $50.53 | -1.80 | -3.4% | $52.40 | $53.75 | $49.57 | 487,936 | |
| $52.33 | +2.63 | +5.3% | $49.11 | $54.78 | $48.64 | 1,150,314 | |
| $49.70 | +1.80 | +3.8% | $48.90 | $50.41 | $47.58 | 808,489 | |
| $47.90 | +2.47 | +5.4% | $45.94 | $48.24 | $45.44 | 587,920 | |
| $45.43 | -3.61 | -7.4% | $49.10 | $49.10 | $44.47 | 571,287 | |
| $49.04 | +2.70 | +5.8% | $48.01 | $50.16 | $46.09 | 881,330 | |
| $46.34 | +1.29 | +2.9% | $45.54 | $46.71 | $45.54 | 410,048 | |
| $45.05 | -0.03 | -0.1% | $46.05 | $46.37 | $43.32 | 426,382 | |
| $45.08 | -0.145 | -0.3% | $45.03 | $45.87 | $43.36 | 434,124 | |
| $45.23 | -0.495 | -1.1% | $46.18 | $47.55 | $44.05 | 471,526 | |
| $45.72 | +0.34 | +0.7% | $44.84 | $46.37 | $44.79 | 640,962 | |
| $45.38 | +1.90 | +4.4% | $43.90 | $46.08 | $43.27 | 617,731 | |
| $43.48 | -0.57 | -1.3% | $43.10 | $45.42 | $41.83 | 592,253 | |
| $44.05 | +0.91 | +2.1% | $43.13 | $44.78 | $41.60 | 849,800 | |
| $43.14 | +0.37 | +0.9% | $42.27 | $44.14 | $41.67 | 844,300 | |
| $42.77 | +1.52 | +3.7% | $41.20 | $42.89 | $40.00 | 711,500 | |
| $41.25 | +4.97 | +13.7% | $36.67 | $41.78 | $36.28 | 1,033,400 | |
| $36.28 | +1.82 | +5.3% | $35.01 | $37.26 | $35.00 | 1,434,200 | |
| $34.46 | -1.58 | -4.4% | $37.07 | $37.24 | $33.38 | 1,041,400 | |
| $36.04 | +1.91 | +5.6% | $34.69 | $36.30 | $33.99 | 1,578,500 | |
| $34.13 | +2.45 | +7.7% | $31.28 | $34.32 | $30.88 | 982,100 | |
| $31.68 | -2.37 | -7.0% | $33.72 | $34.36 | $31.12 | 1,112,300 | |
| $34.05 | +2.20 | +6.9% | $39.45 | $40.50 | $33.02 | 7,310,200 | |
| $31.85 | -0.16 | -0.5% | $31.96 | $33.28 | $30.71 | 855,200 | |
| $32.01 | +1.42 | +4.6% | $33.31 | $33.31 | $30.11 | 1,483,400 | |
| $30.59 | -0.80 | -2.5% | $30.91 | $31.75 | $30.53 | 355,500 | |
| $31.39 | -1.60 | -4.8% | $33.02 | $33.02 | $30.96 | 613,800 | |
| $32.99 | -0.29 | -0.9% | $34.44 | $34.44 | $30.88 | 667,800 | |
| $33.28 | -0.64 | -1.9% | $34.45 | $35.41 | $32.50 | 1,167,900 | |
| $33.92 | -1.52 | -4.3% | $35.20 | $36.03 | $33.77 | 564,100 | |
| $35.44 | -0.54 | -1.5% | $36.74 | $37.31 | $35.32 | 610,600 | |
| $35.98 | -0.67 | -1.8% | $36.61 | $36.80 | $34.99 | 645,500 | |
| $36.65 | +2.23 | +6.5% | $34.40 | $37.24 | $33.55 | 674,500 | |
| $34.42 | -1.41 | -3.9% | $35.82 | $35.82 | $33.66 | 356,500 | |
| $35.83 | -0.83 | -2.3% | $36.11 | $37.09 | $34.57 | 1,144,100 | |
| $36.66 | -4.37 | -10.7% | $41.14 | $41.38 | $36.57 | 658,400 | |
| $41.03 | +2.04 | +5.2% | $39.43 | $42.24 | $39.37 | 893,200 | |
| $38.99 | +0.39 | +1.0% | $38.87 | $39.92 | $38.04 | 661,300 | |
| $38.60 | -0.60 | -1.5% | $40.20 | $41.48 | $38.45 | 2,590,700 | |
| $39.20 | +0.20 | +0.5% | $39.91 | $41.90 | $39.13 | 554,800 | |
| $39.00 | +0.53 | +1.4% | $40.25 | $40.89 | $38.57 | 637,200 | |
| $38.47 | +0.90 | +2.4% | $37.22 | $39.02 | $35.98 | 526,000 | |
| $37.57 | +1.13 | +3.1% | $36.17 | $38.50 | $36.17 | 442,600 | |
| $36.44 | -1.54 | -4.1% | $38.08 | $38.30 | $35.49 | 619,900 | |
| $37.98 | -1.59 | -4.0% | $39.35 | $40.69 | $37.40 | 389,100 | |
| $39.57 | -2.23 | -5.3% | $40.74 | $42.79 | $39.31 | 478,600 | |
| $41.80 | +1.34 | +3.3% | $39.45 | $43.78 | $39.20 | 540,700 | |
| $40.46 | -2.05 | -4.8% | $41.06 | $42.00 | $40.38 | 456,200 | |
| $42.51 | -2.77 | -6.1% | $44.57 | $45.56 | $42.29 | 717,000 | |
| $45.28 | +4.11 | +10.0% | $44.48 | $47.98 | $44.26 | 1,365,300 | |
| $41.17 | -0.67 | -1.6% | $41.57 | $42.62 | $40.75 | 557,500 | |
| $41.84 | -0.02 | 0.0% | $41.67 | $42.44 | $39.83 | 687,000 | |
| $41.86 | -2.88 | -6.4% | $44.36 | $44.74 | $41.69 | 410,000 | |
| $44.74 | +0.55 | +1.2% | $44.09 | $45.39 | $43.80 | 375,300 | |
| $44.19 | -0.92 | -2.0% | $45.84 | $45.84 | $43.73 | 561,700 | |
| $45.11 | +1.83 | +4.2% | $43.27 | $46.48 | $43.27 | 441,929 | |
| $43.28 | +0.17 | +0.4% | $43.47 | $44.64 | $42.56 | 677,251 | |
| $43.11 | +1.21 | +2.9% | $42.98 | $44.79 | $40.72 | 528,000 | |
| $41.90 | -3.60 | -7.9% | $45.50 | $45.99 | $41.78 | 478,200 |
- Ticker
- NASDAQ:TRAX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 3, 2026
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Oct 13, 2026
Investor Presentation (October 2026)
Investor deck · 51 slides
Latest news
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 3, 2026
Closed $49.04 (+5.8%) on Nov 4, 2026
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
Nov 3, 2026
Closed $49.04 (+5.8%) on Nov 4, 2026
First Tracks Biotherapeutics Announces $200 Million Private Placement
Oct 15, 2026
Closed $36.04 (+5.6%) on Oct 15, 2026
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
Oct 12, 2026
Closed $34.05 (+6.9%) on Oct 12, 2026
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
Oct 11, 2026
Closed $34.05 (+6.9%) on Oct 12, 2026
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
Aug 26, 2026
Closed $44.74 (+1.2%) on Aug 27, 2026
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Aug 12, 2026
Closed $44.03 (-4.6%) on Aug 13, 2026
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Closed $16.90 (-6.9%) on May 15, 2026
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
Apr 20, 2026
Closed $18.60 (-17.4%) on Apr 20, 2026
First Tracks Biotherapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 10 in the last 12 months · 10 in all · newest Nov 3, 2026 · oldest 2026
- Decks
- 1 deck · latest Oct 13, 2026
Where First Tracks Biotherapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TRAX · Home listing · This page | NASDAQ | United States | USD |
| BMV:TRAX | BMV | Mexico | MXN |
| BOATS:TRAX | BOATS | United States | USD |
| BIVA:TRAX | BIVA | Mexico | MXN |
| Dusseldorf:B43 | Dusseldorf | Germany | USD |
| Hamburg:B43 | Hamburg | Germany | EUR |
Valuation
Price/book 11.6× against a median of 5.0×: the highest of 10 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.60B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 11.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.80
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| First Tracks Biotherapeutics, Inc. · NASDAQ:TRAX | US$1.75B | US$1.60B | n/a | n/a | n/a | 11.6× | n/a | 0.0× | 1.80 |
| Zymeworks Inc. · NASDAQ:ZYME | US$1.84B | US$2.08B | 42.5× | 7.8× | 40.6× | 7.1× | 16.3% | 1.3× | 0.69 |
| Vera Therapeutics, Inc. · NASDAQ:VERA | US$1.84B | US$1.53B | n/a | 149× | n/a | 5.5× | n/a | 0.2× | 1.13 |
| Hemab Therapeutics Holdings, Inc. · NASDAQ:COAG | US$1.84B | US$1.41B | n/a | n/a | n/a | 4.3× | n/a | 0.0× | 0.61 |
| Braveheart Bio, Inc. · NASDAQ:BRVE | US$1.84B | US$1.71B | n/a | n/a | n/a | 3.7× | n/a | 0.0× | n/a |
| Septerna, Inc. · NASDAQ:SEPN | US$1.84B | US$1.38B | n/a | 14.3× | n/a | 4.3× | −61.3% | 0.1× | 0.95 |
| Replimune Group, Inc. · NASDAQ:REPL | US$1.81B | US$1.60B | n/a | n/a | n/a | 8.8× | n/a | 0.5× | 0.78 |
| Neuren Pharmaceuticals Limited · ASX:NEU | US$1.76B | US$1.57B | 87.3× | 36.7× | 108× | 8.0× | 47.1% | 0.0× | n/a |
| Stoke Therapeutics, Inc. · NASDAQ:STOK | US$1.75B | US$1.43B | n/a | 50.8× | n/a | 5.0× | −862.1% | 0.0× | 0.78 |
| Maze Therapeutics, Inc. · NASDAQ:MAZE | US$1.74B | US$1.39B | n/a | 69.6× | n/a | 4.1× | −757.4% | 0.1× | 0.66 |
| Lycia Therapeutics, Inc. · NASDAQ:LYCA | US$1.72B | US$1.60B | n/a | 237× | n/a | n/a | −540.9% | n/a | n/a |
| Median of the others | US$1.82B | US$1.55B | 64.9× | 50.8× | 74.1× | 5.0× | −301.1% | 0.1× | 0.78 |
Forecasts
9 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 75.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.87 · 10 analysts
Team and board
| Officer | Role |
|---|---|
| Nick Montemarano | Vice President, Investor Relations |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · After close | +5.8% |
| Q2 2026 | Aug 12, 2026 · After close | −4.5% |
| Q1 2026 | May 15, 2026 | −2.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 51 slides | Oct 13, 2026 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock Closed: US$200M raised · US$32.75 a share · Leerink Partners +3 Dealers: Leerink Partners, Piper Sandler, UBS Investment Bank, Wells Fargo Securities Buyers: Affinity Asset Advisors, LLC; First Light Asset Management; Sirenia Capital Management LP; TCGX; Trails Edge Capital Partners; Vestal Point Capital Use of proceeds: General corporate purposes, including clinical development of ANB033, a CD122 antagonist | Nov 3, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | 0 | |
| Cost of revenue | 139.6M | 152.3M | |
| Gross profit | -139.6M | -152.3M | |
| Research and development | 139.6M | 152.3M | 97.6M |
| Selling, general and administrative | 39.4M | 28.8M | 20.9M |
| Operating income | -179.0M | -181.1M | -118.5M |
| Depreciation and amortization | 2.42M | 2.40M | 2.38M |
| EBITDA | -176.6M | -178.7M | -116.1M |
| Income before tax | -166.1M | -163.7M | -106.2M |
| Net income | -166.1M | -163.7M | -106.2M |
| Earnings per share, basic | -4.78 | -4.71 | -3.05 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 238.2M | 123.1M | 36.0M |
| Short-term investments | 73.4M | 262.3M | 354.9M |
| Current assets | 316.4M | 389.9M | 398.6M |
| Total assets | 330.5M | 441.9M | 444.1M |
| Accounts payable | 3.11M | 3.79M | 2.42M |
| Current liabilities | 31.0M | 36.2M | 18.2M |
| Total debt | 14.1M | 16.0M | 17.8M |
| Total liabilities | 43.1M | 50.3M | 34.3M |
| Shareholders' equity | 287.5M | 391.6M | 409.8M |
| Shares outstanding | 34.7M | 34.7M | 34.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -142.9M | -125.8M | -93.0M |
| Capital spending | -87.0K | -358.0K | -807.0K |
| Free cash flow | -143.0M | -126.2M | -93.8M |
| Cash from investing | 228.0M | 95.4M | 144.8M |
| Cash from financing | 30.0M | 117.5M | -87.1M |
| Change in cash | 115.1M | 87.1M | -35.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
All 100 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Oct 30, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| S-1 · Registration statement | Oct 26, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 20, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 15, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Aug 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 3/A · Initial statement of ownership, amended | Aug 7, 2026 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 7, 2026 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 22, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 12, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 12, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 12, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 12, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 12, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 12, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | May 15, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 8, 2026 | Other filings | SEC |
| S-1 · Registration statement | May 8, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 6, 2026 | Other filings | SEC |
| DRS · Draft registration statement | May 1, 2026 | Offer document | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 23, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 20, 2026 | Acquisition or disposal | SEC |
| S-8 · Registration statement for employee plans | Apr 17, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| SEC STAFF ACTION | Apr 1, 2026 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Apr 1, 2026 | Other filings | SEC |
| 10-12B/A | Mar 27, 2026 | Other filings | SEC |
| 10-12B | Mar 3, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Feb 6, 2026 | Offer document | SEC |
Cap table
Built by 6ix from First Tracks Biotherapeutics, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 42,017,901
- Fully diluted
- 42,017,901
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 42,017,901 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 42,017,901 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John Schmid Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); AnaptysBio, Inc. (Director · Since at least Feb 2, 2018); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past) | Director · Since at least Apr 1, 2026 |
| John Orwin Other companies: CARGO Therapeutics, Inc. (Director · Since at least Nov 9, 2023); AnaptysBio, Inc. (Board Chairman of First Tracks Bio Former CEO of Relypsa · Since at least Sep 15, 2023); Travere Therapeutics, Inc. (Director · Since at least Mar 23, 2017); Atreca Inc (PRESIDENT & CEO, Director · Jun 19, 2019 – Apr 11, 2024 · Past); Seagen Inc (Director · Jan 10, 2014 – Dec 14, 2023 · Past); Relypsa Inc (President & CEO, Director · Nov 14, 2013 – Sep 1, 2016 · Past); Affymax Inc (Director · Apr 12, 2010 – Jun 27, 2013 · Past); NeurogesX Inc (Director · Nov 19, 2009 – Jun 7, 2012 · Past) | Director · Since at least Apr 1, 2026 |
| Dennis M Fenton Other companies: AnaptysBio, Inc. (Director · Since at least Mar 5, 2018); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); XenoPort Inc (Director · May 17, 2016 – Jul 5, 2016 · Past); Pfenex Inc (Director · May 6, 2016 – May 5, 2017 · Past) | Director · Since at least Apr 1, 2026 |
| Rita Jain Other companies: SAB Biotherapeutics, Inc. (Director · Since at least Jan 5, 2026); Avalo Therapeutics, Inc. (Director · Since at least Jun 17, 2025); Celldex Therapeutics, Inc. (Director · Since at least Jun 13, 2024); AnaptysBio, Inc. (Director · Since at least Jan 3, 2024) | Director · Since at least Apr 1, 2026 |
| J Anthony Ware Other companies: AnaptysBio, Inc. (Director · Since at least Aug 22, 2017) | Director · Since at least Apr 1, 2026 |
| Magda Marquet Other companies: Immix Biopharma, Inc. (Director · Since at least May 22, 2026) | Director · Since at least Jun 15, 2026 |
| Nick Montemarano Other companies: AnaptysBio, Inc. (Executive Director, Investor Relations · Since at least Mar 3, 2026) | Vice President, Investor Relations · Since at least Nov 3, 2026 |
| Benjamin Stone | Chief Business Officer · Since at least Apr 20, 2026 |
Log in to ask 6ix AI your own questions about First Tracks Biotherapeutics, Inc.